Skip to content
Ashvattha Therapeutics
Ashvattha Therapeutics
  • About Us
    • Senior Management Team
    • Board of Directors
    • Clinical Advisory Board
  • Technology
  • Pipeline
    • Overview
    • Migaldendranib (MGB)
  • News
  • Resources
  • Careers
  • Contact
Ashvattha Therapeutics
  • About Us
    • Senior Management Team
    • Board of Directors
    • Clinical Advisory Board
  • Technology
  • Pipeline
    • Overview
    • Migaldendranib (MGB)
  • News
  • Resources
  • Careers
  • Contact

Resource Type: Media

Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances

First patient enrolled in phase 1/2 study of hydroxyl dendrimer imaging agent

Economic Forecast 2023: New challenges in biotech’s ‘valley of death’

Biospace Movers & Shakers: Maravai, Predictive Oncology, Exagen and More Tap New Execs

Enrollment underway in phase 2 study of subcutaneous anti-VEGF wet AMD, DME candidate

Ashvattha previews plans for long Covid trial in mid-2023

Clinical Trials Arena

Ashvattha’s OP-101 boosts clinical outcomes in Phase IIa Covid-19 trial

Clinical Trials Arena

Getting Across Tissue Barriers for Precise Delivery of Drugs with Jeff Cleland Ashvattha Therapeutics

Empowered Patient Podcast

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

Pharma’s almanac

What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

Pharma’s almanac

Older posts
Page1 Page2 Next →

Recent Posts

  • Ashvattha Therapeutics to Present Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Disease at ARVO
  • Ashvattha Therapeutics to Present at ARVO, Retina World Congress, and AOS Annual Meeting
  • Ashvattha Therapeutics Accelerates Clinical Development Strategy with Leadership Appointment of Six Leading Retinal Specialists to Clinical Advisory Board
  • Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
  • Ashvattha to Present at Upcoming Angiogenesis, Exudation, and Degeneration 2025 and BIO CEO Conferences

Recent Comments

    Archives

    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • June 2024
    • May 2024
    • February 2024
    • January 2024
    • November 2023
    • October 2023
    • August 2023
    • May 2023
    • April 2023
    • February 2023
    • January 2023
    • October 2022
    • September 2022
    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • September 2021
    • June 2021
    • May 2021
    • April 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • June 2020
    • May 2020

    Categories

    • In the News
    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Howdy, this is Creativo

    We just added a brand new Off Canvas Sidebar. You can change the content you see here by going to Appearance -> Widgets -> Off Canvas Sidebar.

    Of course you can also change the design of this sidebar by going to Appearance -> Theme Options -> Off Canvas Sidebar.

    Change everything from: background color, font color, font size, sidebar headings and more.

    © Copyright 2025 Ashvattha Therapeutics.
    • Privacy Policy
    © 2025 Ashvattha Therapeutics • Built with GeneratePress